Literature DB >> 22941427

Nutrigenomics and nutrigenetics in inflammatory bowel diseases.

Lisa Gruber1, Pia Lichti, Eva Rath, Dirk Haller.   

Abstract

Inflammatory bowel diseases (IBD) including ulcerative colitis and Crohn's disease are chronically relapsing, immune-mediated disorders of the gastrointestinal tract. A major challenge in the treatment of IBD is the heterogenous nature of these pathologies. Both, ulcerative colitis and Crohn's disease are of multifactorial etiology and feature a complex interaction of host genetic susceptibility and environmental factors such as diet and gut microbiota. Genome-wide association studies identified disease-relevant single-nucleotide polymorphisms in approximately 100 genes, but at the same time twin studies also clearly indicated a strong environmental impact in disease development. However, attempts to link dietary factors to the risk of developing IBD, based on epidemiological observations showed controversial outcomes. Yet, emerging high-throughput technologies implying complete biological systems might allow taking nutrient-gene interactions into account for a better classification of patient subsets in the future. In this context, 2 new scientific fields, "nutrigenetics" and "nutrigenomics" have been established. "Nutrigenetics," studying the effect of genetic variations on nutrient-gene interactions and "Nutrigenomics," describing the impact of nutrition on physiology and health status on the level of gene transcription, protein expression, and metabolism. It is hoped that the integration of both research areas will promote the understanding of the complex gene-environment interaction in IBD etiology and in the long-term will lead to personalized nutrition for disease prevention and treatment. This review briefly summarizes data on the impact of nutrients on intestinal inflammation, highlights nutrient-gene interactions, and addresses the potential of applying "omic" technologies in the context of IBD.

Entities:  

Mesh:

Year:  2012        PMID: 22941427     DOI: 10.1097/MCG.0b013e31825ca21a

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  10 in total

Review 1.  Molecular basis of the irritable bowel syndrome.

Authors:  Anna Vaiopoulou; Georgios Karamanolis; Theodora Psaltopoulou; George Karatzias; Maria Gazouli
Journal:  World J Gastroenterol       Date:  2014-01-14       Impact factor: 5.742

Review 2.  Immunomodulation by dietary long chain omega-3 fatty acids and the potential for adverse health outcomes.

Authors:  Jenifer I Fenton; Norman G Hord; Sanjoy Ghosh; Eric A Gurzell
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2013-09-30       Impact factor: 4.006

Review 3.  Intestinal epithelial cell metabolism at the interface of microbial dysbiosis and tissue injury.

Authors:  Eva Rath; Dirk Haller
Journal:  Mucosal Immunol       Date:  2022-05-09       Impact factor: 8.701

4.  Short chain fatty acids ameliorate immune-mediated uveitis partially by altering migration of lymphocytes from the intestine.

Authors:  Yukiko K Nakamura; Cathleen Janowitz; Christina Metea; Mark Asquith; Lisa Karstens; James T Rosenbaum; Phoebe Lin
Journal:  Sci Rep       Date:  2017-09-18       Impact factor: 4.379

5.  Acrylamide exposure aggravates the development of ulcerative colitis in mice through activation of NF-κB, inflammatory cytokines, iNOS, and oxidative stress.

Authors:  Keyvan Amirshahrokhi
Journal:  Iran J Basic Med Sci       Date:  2021-03       Impact factor: 2.699

Review 6.  Nutritional Treatment in Crohn's Disease.

Authors:  Giacomo Caio; Lisa Lungaro; Fabio Caputo; Eleonora Zoli; Fiorella Giancola; Giuseppe Chiarioni; Roberto De Giorgio; Giorgio Zoli
Journal:  Nutrients       Date:  2021-05-12       Impact factor: 5.717

7.  Bovine colostrum increases pore-forming claudin-2 protein expression but paradoxically not ion permeability possibly by a change of the intestinal cytokine milieu.

Authors:  Peggy Bodammer; Claus Kerkhoff; Claudia Maletzki; Georg Lamprecht
Journal:  PLoS One       Date:  2013-05-23       Impact factor: 3.240

8.  The effect of turmeric (Curcuma longa) extract on the functionality of the solute carrier protein 22 A4 (SLC22A4) and interleukin-10 (IL-10) variants associated with inflammatory bowel disease.

Authors:  Mark J McCann; Sarah Johnston; Kerri Reilly; Xuejing Men; Elaine J Burgess; Nigel B Perry; Nicole C Roy
Journal:  Nutrients       Date:  2014-10-13       Impact factor: 5.717

9.  Sepsis in preterm infants causes alterations in mucosal gene expression and microbiota profiles compared to non-septic twins.

Authors:  María Cernada; Christine Bäuerl; Eva Serna; Maria Carmen Collado; Gaspar Pérez Martínez; Máximo Vento
Journal:  Sci Rep       Date:  2016-05-16       Impact factor: 4.379

10.  Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD.

Authors:  Thomas Lee; Thomas Clavel; Kirill Smirnov; Annemarie Schmidt; Ilias Lagkouvardos; Alesia Walker; Marianna Lucio; Bernhard Michalke; Philippe Schmitt-Kopplin; Richard Fedorak; Dirk Haller
Journal:  Gut       Date:  2016-02-04       Impact factor: 23.059

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.